Médecine translationnelle
Libre accès
ISSN: 2161-1025
ISSN: 2161-1025
Geeta Shroff
Background: The present study evaluated the efficacy and safety of human embryonic somatic cell (hESC) therapy in patients with Cerebral Palsy (CP).
Methods: This analysis comprised patients (30 days-18 years) with predictable identification of CP. The study consisted of four treatment phases (T1, T2, T3, T4) separated by gap phases. Efficacy of hESC therapy was evaluated supported Gross Motor Function Classification Scores Expanded and Revised (GMFCS-E & R; 1-good to 5-bad).
Results: Ninety one patients were included and every one received hESC therapy in T1, 66 patients returned for T2, 38 patients for T3, and 15 patients for T4. General, 31.2% patients attained GMFCS-E & R score 1 throughout the study with dissimilar number of patients attaining GMFCS score 1 by the top of every single treatment phase (T1: 6 [6.6%]; T2: 7 [10.6%]; T3: 11 [28.9%]; and T4: 5 [33.3%]). All patients in up to two years (n=10), 2-4 years (n=10), 4-6 years (n=9), and 6- 12 years (n=8) age bracket s except one among the 5 patients within the age group of 12-18 years transitioned from GMFCSE & R score 5 to lower scores by end of T1. Most patients transitioned to GMFCS-E & R score 2 (n=34) from upper scores by end of T2. Eleven (11) patients accomplished GMFCS-E and R score 1 by end of T3. No severe adverse proceedings were perceived.
Conclusion: Use of hESC treatment in patients with CP is actual and safe. hESC therapy has established significant enhancement in GMFCS-E and R scale.